Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548818 · ClinicalTrials.gov registry record
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 9
- Enrollment target
NCT03548818 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 9 participants.
The verdict
NCT03548818 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of infections) are the result of biochemical processes and upregulation of specific genes, which lead to enhanced functionality of this immune cell population.
Interventions
- DRUG Interferon Gamma-1B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2020-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03548818
The ClinicalTrials.gov registry entry for NCT03548818 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon Gamma-1B is the first listed.
NCT03548818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03548818 about?
NCT03548818 is a clinical study titled "Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease". The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD ...
What is the current status of trial NCT03548818?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2018-05-16. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03548818?
The interventions under investigation include: Interferon Gamma-1B (DRUG).
Who is sponsoring clinical trial NCT03548818?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.